234 Church Street |
|
New Haven, CT 06510 | VIA EDGAR |
April 3, 2018
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4561
Washington, D.C. 20549
Attn: Jeffrey Gabor
Re: Biohaven Pharmaceutical Holding Company Ltd.
Registration Statement on Form S-1
File No. 333-224123
Acceleration Request
Requested Date: Thursday, April 5, 2018
Requested Time: 4:30 P.M. Eastern Daylight Time
Dear Mr. Gabor:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-224123) to become effective on April 5, 2018 at 4:30 p.m., Eastern Daylight Time, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared effective, please orally confirm that event with Katie Kazem of Cooley LLP, counsel to the Registrant, at (703) 456-8043 or Paula Fleckenstein of Cooley LLP at (703) 456-8707.
| Very truly yours, | |
|
| |
| Biohaven Pharmaceutical Holding Company Ltd. | |
|
| |
|
|
|
| By: | /s/ James Engelhart |
|
|
|
|
| James Engelhart |
|
| Chief Financial Officer |
cc: | Darren K. DeStefano, Cooley LLP |
|
| Brian F. Leaf, Cooley LLP |
|
| Patrick O’Brien, Ropes & Gray LLP |
|